1349 On Other Exchanges
Symbol
Exchange
1349 is not on other exchanges.

shanghai fudan-zhangjiang-h (1349) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SHANGHAI FUDAN-ZHANGJIANG-H (1349)

Related News

No related news articles were found.

shanghai fudan-zhangjiang-h (1349) Related Businessweek News

No Related Businessweek News Found

shanghai fudan-zhangjiang-h (1349) Details

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells bio-pharmaceutical products. It offers genetic engineering drugs, including recombinant tissue type plasminogen activator for heart infarction; recombinant human lymphotoxin a-derivatives and Vincristine sulphate liposome that have completed Phase II clinical trials for tumors; recombinant human tumor necrosis recipient Fc fusion protein and rhTNFR(m):Fc for arthritis; PTH that has completed Phase I clinical trials for osteoporosis; CD30-MMAE and Nanoparticle Albumin-bound Paclitaxel that are in pre-clinical study for tumors; and Avastin that has completed pre-clinical study for tumors. The company also provides anti-sclerostin mab that is in pre-clinical study for osteoporosis; and PCSK9 that is in pre-clinical study for hypercholesterolemia. In addition, it offers photodynamic therapy drugs, such as Hemoporfin for port wine stain; Deuteroporphyrin that is in Phase II clinical trials for tumors; Aminolevulinic acid, which is in Phase II clinical trial for cervical diseases infected by HPV; and Aminolevulinic acid that has submitted application for clinical trials for acne, as well as is in pre-clinical study for brain gliomas and basal cell carcinoma. Further, the company provides liposomal drugs comprising Libod, a liposome doxorubicin injection for tumors; and Xenon liposome that is in pre-clinical study for strokes. Additionally, it offers Antenatal screening diagnostic reagent for Down’s syndrome; and food safety inspection reagents for antibiotics inspection. The company also researches and develops biological and medical technology, pharmaceutical projects, and medical diagnostic products, as well as offers technical and general merchandise, and healthcare services. It has strategic agreement with Shanghai Pharmaceuticals Holding Co., Ltd. The company was founded in 1996 and is based in Shanghai, the People's Republic of China.

593 Employees
Last Reported Date: 08/23/16
Founded in 1996

shanghai fudan-zhangjiang-h (1349) Top Compensated Officers

Co-Founder, Executive Chairman, General Manag...
Total Annual Compensation: CNY2.0M
Co-Founder, Deputy General Manager and Execut...
Total Annual Compensation: CNY1.3M
Deputy General Manager and Executive Director
Total Annual Compensation: CNY1.3M
Compensation as of Fiscal Year 2015.
shanghai fudan-zhangjiang-h
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2016

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. reported unaudited consolidated earnings results for the six months ended June 30, 2016. For the six months, the company’s revenue was RMB 241,910,000 against RMB 214,224,000 a year ago. Operating profit was RMB 51,345,000 against RMB 45,026,000 a year ago. Profit before income tax was RMB 49,013,000 against RMB 42,306,000 a year ago. Profit for the period attributable to shareholders of the company was RMB 45,936,000 or RMB 0.0498 basic and diluted per share against RMB 39,661,000 or RMB 0.0430 basic and diluted per share a year ago. Total comprehensive income for the period attributable to shareholders of the company was RMB 45,936,000 against RMB 39,661,000 o a year ago. EBITDA was RMB 65,524,000 compared to RMB 63,433,000 a year ago. The main reason of increase in revenue was that sales of LIBOd and ALA. Net cash generated from operating activities was RMB 44,020,000 against RMB 19,403,000 a year ago. Purchase of property, plant and equipment was RMB 15,644,000 against RMB 21,485,000 a year ago. Purchase of intangible assets was RMB 52,000 against RMB 831,000 a year ago.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2016

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. reported unaudited consolidated earnings results for the six months ended June 30, 2016. For six months, revenue was RMB 241,910,000 against RMB 214,224,000 a year ago. Operating profit was RMB 51,345,000 against RMB 45,026,000 a year ago. Profit before income tax was RMB 49,013,000 against RMB 42,306,000 a year ago. Profit attributable to shareholders of the company was RMB 45,936,000 against RMB 39,661,000 a year ago. EBITDA was RMB 65,524,000 against RMB 63,433,000 a year ago. Basic and diluted earnings per share for profit attributable to the shareholders of the company were RMB 0.0498 against RMB 0.0430 a year ago.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. to Report First Half, 2016 Results on Aug 09, 2016

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. announced that they will report first half, 2016 results on Aug 09, 2016

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

1349 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 1349.
View Industry Companies
 

Industry Analysis

1349

Industry Average

Valuation 1349 Industry Range
Price/Earnings 36.3x
Price/Sales 8.0x
Price/Book 6.5x
Price/Cash Flow 36.3x
TEV/Sales 7.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact SHANGHAI FUDAN-ZHANGJIANG-H, please visit www.fd-zj.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.